For help on how to get the results you want, see our search tips.
2 results
Categories
Human Remove Human filter
Referral status
European Commission final decision Remove European Commission final decision filter
CMDh final position Remove CMDh final position filter
Referral authorisation model
Centrally authorised product(s) Remove Centrally authorised product(s) filter
Centrally and nationally authorised products (mixed) Remove Centrally and nationally authorised products (mixed) filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
Variation Remove Variation filter
No further action Remove No further action filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
Referral safety status
Yes Remove Yes filter
-
List item
Referral: Janus kinase inhibitors (JAKi)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020